COVID-19 Pandemic and medicine monopolies

COVID pandemic exposed how medicine monopolies delayed access to vaccines and treatments

During the COVID pandemic 2020-22, AFTINET campaigned on the issue of access to pandemic-related medicines. COVID has demonstrated the limitations of the global health system and the Intellectual WTO Property (IP) regime that shaped the global response to the pandemic. IP rules gave a few pharmaceutical companies twenty-year patents on new COVID vaccines, which meant they controlled both the quantity and prices. Most vaccines were sold to high-income countries at high prices. This resulted in long delays in access to vaccines for low and low-middle income countries leading to lower vaccination rates. There was even less access to treatments when they became available.

Developing countries in October 2020 proposed a temporary waiver of WTO IP rules to share intellectual property and enable global production of more vaccines and treatments at affordable prices for low- and middle-income countries. AFTINET worked with a broad coalition of public health, union, aid and development and human rights organisations to generate public support for this proposal and to lobby the Australian government to support it. We commissioned a survey which showed that most Australian supported the temporary waiver and organised a petition with 50,000 signatures, organised rallies exposing pharmaceutical companies’ profiteering, and pressured the government and opposition parties to state publicly that they would support the waiver. However, at the WTO negotiations the government took a neutral stance, trying to broker a compromise between supporters and opponents of the waiver.

The waiver proposal was delayed for over 18 months by rich countries, lobbied by pharmaceutical companies, until the peak of the pandemic was over. The June 2022 WTO Ministerial decision on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) was a watered-down version of the waiver originally proposed which had little effect and applied only to vaccines. A decision on COVID treatments and other pandemic-related products was postponed and has still not been made.

In early 2022, for every dose of mRNA vaccine delivered to low-income countries, 56 were delivered to rich countries. Vaccination rates in low-income countries were less than 20% by January 2022, and were still only at 32% in September 2023. These delays contributed to the estimated 17.2 million deaths due to COVID, the majority of which were in low- and low-middle income countries.

The World Health Organisation is now negotiating a Pandemic Agreement to apply to future pandemics, which is intended to learn from the mistakes of the COVID pandemic. AFTINET is lobbying the Australian government to support temporary waivers on monopolies and other actions to share intellectual property and technology for all pandemic-related products, to ensure more equitable access for low- and middle-income countries.  See our submission below.

Resources:

 

Updated September 2023.

States have human rights obligations to support TRIPS Waiver, says International Commission of Jurists

November 11, 2021: Ahead of critical meetings in the World Trade Organisation (WTO) this month, the International Commission of Jurists (ICJ) has published a legal opinion detailing the human rights obligations of countries in regards to the proposed TRIPS Waiver on COVID-19 vaccine monopolies.

Media Release: ‘Each-way bet’: Trade Minister declines to co-sponsor waiver on COVID vaccine monopolies

November 4: On the eve of an important World Trade Organisation (WTO) meeting on intellectual property this week, the Government has revealed that Australia will not co-sponsor a proposal to waive commercial monopolies on COVID19 vaccines, as Shadow Trade Minister Madeleine King MP and campaigners have urged.

WTO negotiations on vaccine monopolies continue as leaked contracts reveals Pfizer’s abuse of monopoly powers

October 21, 2021: Last week’s meeting of the World Trade Organisation (WTO) Trade-Related Intellectual Property Rights (TRIPS) Council failed to decide on the temporary waiver on monopoly rights for COIVD-19 vaccines and related products, despite support from over 100 WTO member countries and numerous reports and protests urging it to do so.

Covid medicine monopolies waiver can accelerate global vaccine rollout: major reports

October 11, 2021: Two major reports have exposed the failings of the current system of global vaccine production and distribution, recommending both increased emergency donations of vaccines and the temporary waiver of intellectual property (IP) rights at the World Trade Organisation (WTO) to enable production of cheap vaccines in low-income countries.

Pages